Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades

Journal of Neuroinflammation

Volumn 7, Issue , 2010, Pages

  Wang, Mei Jen ^a,b   Huang, Hsin Yi ^a,b   Chen, Wu Fu ^c,d   Chang, Hui Fen ^a   Kuo, Jon Son ^b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GLYCOGEN SYNTHASE KINASE 3BETA; LUCIFERASE; LYMPHOTOXIN; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MIXED LINEAGE KINASE 3; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 11; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CELL NUCLEUS TRANSPLANTATION; CONTROLLED STUDY; DEACETYLATION; DIMERIZATION; DOWN REGULATION; ENZYME INACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNOPRECIPITATION; MICROGLIA; MOLECULAR DYNAMICS; NEUROMODULATION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; RAT; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ANIMAL; CELL LINE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CELL LINE; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; I-KAPPA B PROTEINS; INFLAMMATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; MAP KINASE KINASE KINASES; MICE; MICROGLIA; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650654039     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-7-99     Document Type: Article

References (66)

1. Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005, 26:349-354. 10.1016/j.neurobiolaging.2004.05.010, 15639313.
2. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 2006, 12:1005-1015.
3. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008, 23:474-483. 10.1002/mds.21751, 18044695.
4. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001, 65:391-426. 10.1016/S0301-0082(01)00011-9, 11527574.
5. Jiang H, Guo W, Liang X, Rao Y. Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3β and its upstream regulators. Cell 2005, 120:123-135.
6. Sanchez JF, Sniderhan LF, Williamson AL, Fan S, Chakraborty-Sett S, Maggirwar SB. Glycogen synthase kinase 3β-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor κB signaling. Mol Cell Biol 2003, 23:4649-4662. 10.1128/MCB.23.13.4649-4662.2003, 164840, 12808104.
7. Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K, Kracht M. Phosphorylation of serine 468 by GSK-3β negatively regulates basal p65 NF-κB activity. J Biol Chem 2004, 279:49571-49574. 10.1074/jbc.C400442200, 15465828.
8. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB. Genetic deletion of glycogen synthase kinase-3β abrogates activation of IκBα kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 2004, 279:39541-39554. 10.1074/jbc.M403449200, 15252041.
9. Shen E, Fan J, Peng T. Glycogen synthase kinase-3beta suppresses tumor necrosis factor-alpha expression in cardiomyocytes during lipopolysaccharide stimulation. J Cell Biochem 2008, 104:329-338. 10.1002/jcb.21629, 18027881.
10. Vines A, Cahoon S, Goldberg I, Saxena U, Pillarisetti S. Novel inflammatory role for glycogen synthase-3β in the inhibition of TNF-α and IL-1β induced inflammatory gene expression. J Biol Chem 2006, 281:16985-16990. 10.1074/jbc.M602446200, 16601113.
11. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005, 6:777-784. 10.1038/ni1221, 1933525, 16007092.
12. Huang WC, Lin YS, Wang CY, Tsai CC, Tseng HC, Chen CL, Lu PJ, Chen PS, Qian L, Hong JS, Lin CF. Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology 2009, 128:e275-286. 10.1111/j.1365-2567.2008.02959.x, 2753919, 19175796.
13. Yuskaitis CJ, Jope RS. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 2009, 21:264-273. 10.1016/j.cellsig.2008.10.014, 2630396, 19007880.
14. Colasanti M, Persichini T, Pucchio T, Gremo F, Lauro GM. Human ramified microglial cells produce nitric oxide upon Escherichia coli lipopolysaccharide and tumor necrosis factor alpha stimulation. Neurosci Lett 1995, 200:144-146. 10.1016/0304-3940(95)12101-9, 8614565.
15. Marcus JS, Karackattu SL, Fleegal MA, Sumners C. Cytokine-stimulated inducible nitric oxide synthase expression in astroglia: role of Erk mitogen-activated protein kinase and NF-kappaB. Glia 2003, 41:152-160. 10.1002/glia.10168, 12509805.
16. Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. J Biol Chem 1992, 267:5317-5323.
17. Goossens V, Grooten J, De Vos K, Fiers W. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA 1995, 92:8115-8119. 10.1073/pnas.92.18.8115, 41106, 7667254.
18. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995, 81:495-504. 10.1016/0092-8674(95)90070-5, 7758105.
19. Fillit H, Ding WH, Buee L, Kalman J, Altstiel L, Lawlor B, Wolf-Klein G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 1991, 129:318-320. 10.1016/0304-3940(91)90490-K, 1745413.
20. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994, 165:208-210. 10.1016/0304-3940(94)90746-3, 8015728.
21. Raine CS. Multiple sclerosis: immune system molecule expression in the central nervous system. J Neuropathol Exp Neurol 1994, 53:328-337. 10.1097/00005072-199407000-00002, 8021705.
22. Poloni M, Facchetti D, Mai R, Micheli A, Agnoletti L, Francolini G, Mora G, Camana C, Mazzini L, Bachetti T. Circulating levels of tumor necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett 2000, 287:211-214. 10.1016/S0304-3940(00)01177-0, 10863032.
23. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implication for Parkinson's disease. FASEB J 2002, 16:1474-1476.
24. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tansey MG. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 2006, 26:9365-9375. 10.1523/JNEUROSCI.1504-06.2006, 16971520.
25. Meda L, Cassatella MA, Szendrei GI, Otvos L, Baron P, Villalba M, Ferrari D, Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995, 374:647-650. 10.1038/374647a0, 7715705.
26. Lio D, Annoni G, Licastro F, Crivello A, Forte GI, Scola L, Colonna-Romano G, Arosio B, Galimberti L, Vergani C, Caruso C. Tumor necrosis factor-alpha -308A/G polymorphism is associated with age at onset of Alzheimer's disease. Mech Ageing Dev 2006, 127:567-571. 10.1016/j.mad.2006.01.015, 16516271.
27. McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 2009, 34:163-177. 10.1016/j.nbd.2009.01.006, 2948857, 19320056.
28. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 2008, 5:2-11. 10.1186/1742-2094-5-2, 2211476, 18184433.
29. West M, Mhatre M, Ceballos A, Floyd RA, Grammas P, Gabbita PS, Hamdheydari L, Mai T, Mou S, Pye QN, Stewart C, west S, Williamson KS, Zemlan F, Hensley K. The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem 2004, 91:133-143. 10.1111/j.1471-4159.2004.02700.x, 15379894.
30. Wang M-J, Lin S-Z, Kuo J-S, Huang H-Y, Tzeng S-F, Liao C-H, Chen D-C, Chen W-F. Urocortin modulates inflammatory response and neurotoxicity induced by microglial activation. J Immunol 2007, 179:6204-6214.
31. Ding S, Wu TYH, Brinker A, Peters EC, Hur W, Gray NS, Schultz PG. Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci USA 2003, 100:7632-7637. 10.1073/pnas.0732087100, 164638, 12794184.
32. Covert MW, Leung TH, Gaston JE, Baltimore D. Achieving stability of lipopolysaccharide-induced NF-κB activation. Science 2005, 309:1854-1857. 10.1126/science.1112304, 16166516.
33. Werner SL, Barken D, Hoffmann A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 2005, 309:1857-1861. 10.1126/science.1113319, 16166517.
34. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-kB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003, 22:1313-1324. 10.1093/emboj/cdg139, 151081, 12628924.
35. Yang F, Tang E, Guan K, Wang C-Y. IKKβ plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol 2003, 170:5630-5635.
36. Chen L-F, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001, 293:1653-1657. 10.1126/science.1062374, 11533489.
37. Chen L-F, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 2002, 21:6539-6548. 10.1093/emboj/cdf660, 136963, 12456660.
38. Bhat NR, Zhang P, Lee JC, Hogan EL. Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinase regulate inducible nitric oxide synthase and tumor necrosis factor-α gene expression in endotoxin-stimulated primary glial cultures. J Neurosci 1998, 18:1633-1641.
39. Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 1991, 354:494-496. 10.1038/354494a0, 1749429.
40. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103:239-252. 10.1016/S0092-8674(00)00116-1, 11057897.
41. Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev 2001, 15:1419-1426. 10.1101/gad.888501, 312702, 11390361.
42. Wang X, Destrument A, Tournier C. Physiological roles of MKK4 and MKK7: insights from animal models. Biochim Biophys acta 2007, 1773:1349-1357. 10.1016/j.bbamcr.2006.10.016, 17157936.
43. Xu Z, Maroney AC, Dobrzanski P, Kukekov NV, Greene LA. The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol Cell Biol 2001, 21:4713-4724. 10.1128/MCB.21.14.4713-4724.2001, 87148, 11416147.
44. Gallo KA, Johnson GL. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol 2002, 3:663-672. 10.1038/nrm906, 12209126.
45. Leung IW, Lassam N. The kinase activation loop is the key to mixed lineage kinase-3 activation via both autophosphorylation and hematopoietic progenitor kinase 1 phosphorylation. J Biol Chem 2001, 276:1961-1967. 10.1074/jbc.M004092200, 11053428.
46. Roux PP, Dorval G, Boudreau M, Angers-Loustau A, Morris SJ, Makkerh J, Barker PA. K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK. J Biol Chem 2002, 277:49473-49480. 10.1074/jbc.M203428200, 12388555.
47. Pan J, Zhang Q-G, Zhang G-Y. The neuroprotective effects of K252a through inhibiting MLK3/MKK7/JNK3 signaling pathway on ischemic brain injury in rat hippocampal CA1 region. Neuroscience 2005, 131:147-159. 10.1016/j.neuroscience.2004.09.031, 15680699.
48. Mishra R, Barthwal MK, Sondarva G, Rana B, Wong L, Chatterjee M, Woodgett JR, Rana A. Glycogen synthase kinase-3β induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3. J Biol Chem 2007, 282:30393-30405. 10.1074/jbc.M705895200, 17711861.
49. Leung IW, Lassam N. Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3. J Biol Chem 1998, 273:32408-32415. 10.1074/jbc.273.49.32408, 9829970.
50. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3) inflammation, diseases, and therapeutics. Neurochem Res 2007, 32:577-595. 10.1007/s11064-006-9128-5, 16944320.
51. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002, 277:32124-32132. 10.1074/jbc.M203298200, 12052830.
52. Hoeflich KP, Luo J, Rubie EA, Tsao M-S, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 2000, 406:86-90. 10.1038/35017574, 10894547.
53. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003, 116:1175-1186. 10.1242/jcs.00384, 3006448, 12615961.
54. Haefner B. A model for NF-kappa B regulation by GSK-3 beta. Drug Discov Today 2003, 8:1062-1063. 10.1016/S1359-6446(03)02898-8, 14693463.
55. Steinbrecher KA, Wilson W, Cogswell PC, Baldwin AS. Glycogen synthase kinase 3β functions to specify gene-specific, NF-κB-dependent transcription. Mol Cell Biol 2005, 25:8444-8455. 10.1128/MCB.25.19.8444-8455.2005, 1265740, 16166627.
56. Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, Haegeman G. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol 2002, 64:963-970. 10.1016/S0006-2952(02)01161-9, 12213593.
57. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004, 18:2195-2224. 10.1101/gad.1228704, 15371334.
58. Schmitz ML, Mattioli I, Buss H, Kracht M. NF-kappaB: a multifaceted transcription factor regulated at several levels. Chembiochem 2004, 5:1348-1358. 10.1002/cbic.200400144, 15457532.
59. Gong R, Rifai A, Ge Y, Chen S, Dworkin LD. Hepatocyte growth factor suppresses proinflammatory NFκB activation through GSK3β inactivation in renal tubular epithelial cells. J Biol Chem 2008, 283:7401-7410. 10.1074/jbc.M710396200, 2276324, 18201972.
60. Chen L-F, Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 2004, 5:392-401. 10.1038/nrm1368, 15122352.
61. Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, Sardet C, Jin DY, Emiliani S, Benkirane M. Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003, 278:2758-2766. 10.1074/jbc.M209572200, 12419806.
62. Eom TY, Jope RS. GSK3β N-terminus binding to p53 promotes its acetylation. Mol Cancer 2009, 8:14-20. 10.1186/1476-4598-8-14, 2660897, 19265551.
63. Waetzig V, Czeloth K, Hidding U, Mielke K, Kanzow M, Brecht S, Goetz M, Lucius R, Herdegen T, Hanisch UK. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia 2005, 50:235-246. 10.1002/glia.20173, 15739188.
64. Liu S, Yu S, Hasegawa Y, LaPushin R, Xu H-J, Woodgett JR, Mills GB, Fang X. Glycogen synthase kinase 3β is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem 2004, 279:51075-51081. 10.1074/jbc.M408607200, 15466414.
65. Kim JW, Lee JE, Kim MJ, Cho E-G, Cho S-G. Glycogen synthase kinase 3β is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1). J Biol Chem 2003, 278:13995-14001. 10.1074/jbc.M300253200, 12584189.
66. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007, 32:577-595. 10.1007/s11064-006-9128-5, 1970866, 16944320.